Literature DB >> 12745098

Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk.

Allan D Sniderman1, Annie C St-Pierre, Bernard Cantin, Gilles R Dagenais, Jean-Pierre Després, Benoît Lamarche.   

Abstract

The objective of the present study was to examine concordance/discordance among 4 atherogenic indexes of cardiovascular risk: plasma total cholesterol, low-density lipoprotein (LDL) cholesterol, non-high-density lipoprotein (non-HDL) cholesterol, and apolipoprotein B-100 (apoB). Analyses were conducted in a cohort of 2,103 men without coronary artery disease (CAD) at the onset of the Quebec Cardiovascular Study. Although there were strong and highly significant correlations among the 4 risk indexes (0.78 < r < 0.97), only 50% of all subjects had concordant apoB and LDL cholesterol levels (i.e., values that fell into the same quintile of the population distribution). Moreover, concordance/discordance was not the same throughout the range of both variables; it was greater at the extremes of their respective distributions (65%), but significantly less in the midpoints (<40%). ApoB appeared to be more concordant with non-HDL cholesterol than with LDL cholesterol, although >1/3 of all subjects had discordant levels. Kappa analysis confirmed that there was only fair agreement between apoB and total or LDL cholesterol (0.38 and 0.36, respectively) and only moderate agreement between non-HDL cholesterol and apoB (0.47). Finally, a significant proportion of subjects (528 of 2,103) who had disproportionately higher apoB levels than would have been predicted based on their LDL cholesterol concentrations was more obese and manifested several features of the metabolic syndrome. They also had a significantly increased cardiovascular risk. In summary, plasma apoB and the various cholesterol indexes are complementary rather than competitive indexes of atherosclerotic risk and provide further evidence as to why measurement of apoB should be part of a standard lipoprotein assessment of CAD risk.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12745098     DOI: 10.1016/s0002-9149(03)00262-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  41 in total

Review 1.  Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease.

Authors:  William C Cromwell; Thomas A Barringer
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

Review 2.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

3.  To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?

Authors:  Carl J Lavie; Richard V Milani; James H O'Keefe
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

Review 4.  The evolution and refinement of traditional risk factors for cardiovascular disease.

Authors:  Emil M deGoma; Joshua W Knowles; Fabio Angeli; Matthew J Budoff; Daniel J Rader
Journal:  Cardiol Rev       Date:  2012 May-Jun       Impact factor: 2.644

5.  Low-density lipoprotein cholesterol versus particle number in middle school children.

Authors:  Michele Mietus-Snyder; Kimberly L Drews; James D Otvos; Steven M Willi; Gary D Foster; Russell Jago; John B Buse
Journal:  J Pediatr       Date:  2013-02-14       Impact factor: 4.406

6.  Relation of Combined Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B With Atherosclerosis in Adults With Type 1 Diabetes Mellitus.

Authors:  Petter Bjornstad; Robert H Eckel; Laura Pyle; Marian Rewers; David M Maahs; Janet K Snell-Bergeon
Journal:  Am J Cardiol       Date:  2015-07-16       Impact factor: 2.778

7.  Discordance between non-HDL-cholesterol and LDL-particle measurements: results from the Multi-Ethnic Study of Atherosclerosis.

Authors:  Emil M Degoma; Mat D Davis; Richard L Dunbar; Emile R Mohler; Philip Greenland; Benjamin French
Journal:  Atherosclerosis       Date:  2013-03-26       Impact factor: 5.162

8.  Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.

Authors:  Samia Mora; Michael P Caulfield; Jay Wohlgemuth; Zhihong Chen; H Robert Superko; Charles M Rowland; Robert J Glynn; Paul M Ridker; Ronald M Krauss
Journal:  Circulation       Date:  2015-09-25       Impact factor: 29.690

9.  LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management.

Authors:  William C Cromwell; James D Otvos; Michelle J Keyes; Michael J Pencina; Lisa Sullivan; Ramachandran S Vasan; Peter W F Wilson; Ralph B D'Agostino
Journal:  J Clin Lipidol       Date:  2007-12       Impact factor: 4.766

Review 10.  Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention.

Authors:  Jesús Millán; Xavier Pintó; Anna Muñoz; Manuel Zúñiga; Joan Rubiés-Prat; Luis Felipe Pallardo; Luis Masana; Alipio Mangas; Antonio Hernández-Mijares; Pedro González-Santos; Juan F Ascaso; Juan Pedro-Botet
Journal:  Vasc Health Risk Manag       Date:  2009-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.